{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:38:06Z","timestamp":1762843086870,"version":"build-2065373602"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A world without antibiotics is hard to conceive. They have revolutionized the treatment landscape for bacterial infections, reducing mortality rates and enabling complex medical procedures. However, their widespread use has fueled the rise of antimicrobial resistance, a growing global health threat that demands new antibacterial therapies and strategies to preserve the efficacy of existing treatments. Among promising candidates, antimicrobial compounds (AMCs) offer broad-spectrum antimicrobial activity with a lower risk of resistance development. Recent studies suggest that unfractionated heparin, a commonly used anticoagulant, reduces the antibacterial and endotoxin-neutralizing activity of blood-derived AMCs, likely through ionic interactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Given the prevalence of negatively charged anticoagulants in clinical settings, we aimed to explore the effects of unfractionated heparin, low molecular weight heparin, and fondaparinux on the antibacterial activity of AMCs and antibiotics (colistin, daptomycin, gentamicin, imipenem, ofloxacin, and vancomycin).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our results revealed that both unfractionated and low molecular weight heparin markedly impaired the antibacterial activity of AMCs and positively charged antibiotics, whereas fondaparinux showed no such effect. For instance, exposure to 2.5 IU\/mL of unfractionated and low molecular weight heparin led to a significant increase in the minimal inhibitory and minimal bactericidal concentrations of colistin and gentamicin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      These findings support our hypothesis that specific heparin-based anticoagulants interfere with the activity of blood-derived AMCs and positively charged antibiotics, reducing their efficacy\n                      <jats:italic>in vitro<\/jats:italic>\n                      . Our research aims to provide a foundation for future studies focused on optimizing anticoagulant use in clinical settings, ultimately improving patient outcomes in the ongoing fight against multidrug-resistant bacteria.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1708169","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:33:19Z","timestamp":1762842799000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Influence of heparin-based anticoagulants on antibiotic therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Denisa","family":"Cont","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Schildb\u00f6ck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Kolm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander K. T.","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas H.","family":"Farnleitner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktoria","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Harm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s10295-015-1723-5","article-title":"Natural product discovery: past, present, and future","volume":"43","author":"Katz","year":"2016","journal-title":"J Ind Microbiol Biotechnol"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-64926-4","volume-title":"The experimental chemotherapy of spirilloses","author":"Ehrlich","year":"1910"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1159\/000149583","article-title":"The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize","volume":"82","author":"Bosch","year":"2008","journal-title":"Pharmacology"},{"key":"B4","article-title":"On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. 1929","volume":"79","author":"Fleming","year":"2001","journal-title":"Bull World Health Organ"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e65179","DOI":"10.7759\/cureus.65179","article-title":"The penicillin pioneer: Alexander Fleming's journey to a medical breakthrough","volume":"16","author":"Chhabra","year":"2024","journal-title":"Cureus"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1177\/2150132719886942","article-title":"Assessment of antibiotic prescribing patterns at outpatient pharmacy using world health organization prescribing indicators","volume":"10","author":"Yimenu","year":"2019","journal-title":"J Prim Care Community Health"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70318-9","article-title":"Antibiotic resistance-the need for global solutions","volume":"13","author":"Laxminarayan","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2014.02.035","article-title":"The resistance tsunami, antimicrobial stewardship, and the golden age of microbiology","volume":"171","author":"Prescott","year":"2014","journal-title":"Vet Microbiol"},{"key":"B9","volume-title":"Antimicrobial resistance: global report on surveillance","year":"2014"},{"key":"B10","unstructured":"Tackling drug-resistant infections globally: final report and recommendations: Review on Antimicrobial Resistance\n          \n          \n            \n              O'Neill\n              J\n            \n          \n          \n          2016"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1086\/533452","article-title":"Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE","volume":"197","author":"Rice","year":"2008","journal-title":"J Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.628302","article-title":"Sepsis-pathophysiology and therapeutic concepts","volume":"8","author":"Jarczak","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050","volume":"404","year":"2024","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00474-2","article-title":"Access to effective antimicrobials: a worldwide challenge","volume":"387","author":"Laxminarayan","year":"2016","journal-title":"Lancet"},{"key":"B18","volume-title":"Drug-resistant infections: a threat to our economic future","year":"2017"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv339","article-title":"The innovative medicines initiative's new drugs for bad bugs programme: european public-private partnerships for the development of new strategies to tackle antibiotic resistance","volume":"71","author":"Kostyanev","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"B20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/phar.1868","article-title":"Past, present, and future of antibacterial economics: increasing bacterial resistance, limited antibiotic pipeline, and societal implications","volume":"37","author":"Luepke","year":"2017","journal-title":"Pharmacotherapy"},{"key":"B21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.mib.2019.10.008","article-title":"Antibiotics: past, present and future","volume":"51","author":"Hutchings","year":"2019","journal-title":"Curr Opin Microbiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nature14098","article-title":"A new antibiotic kills pathogens without detectable resistance","volume":"517","author":"Ling","year":"2015","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1016\/j.cell.2023.07.038","article-title":"An antibiotic from an uncultured bacterium binds to an immutable target","volume":"186","author":"Shukla","year":"2023","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(01)00092-5","article-title":"Cationic peptides: effectors in innate immunity and novel antimicrobials","volume":"1","author":"Hancock","year":"2001","journal-title":"Lancet Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2016.00194","article-title":"Antimicrobial peptides: an emerging category of therapeutic agents","volume":"6","author":"Mahlapuu","year":"2016","journal-title":"Front Cell Infect Microbiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2174\/1386207053764576","article-title":"Molecular mechanisms of membrane perturbation by antimicrobial peptides and the use of biophysical studies in the design of novel peptide antibiotics","volume":"8","author":"Lohner","year":"2005","journal-title":"Comb Chem High Throughput Screen"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2013.844227","article-title":"Antimicrobial peptides: new drugs for bad bugs","volume":"14","author":"Steckbeck","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.582779","article-title":"Antimicrobial peptides: classification, design, application and research progress in multiple fields","volume":"11","author":"Huan","year":"2020","journal-title":"Front Microbiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20215426","article-title":"Blood compatibility-an important but often forgotten aspect of the characterization of antimicrobial peptides for clinical application","volume":"20","author":"Harm","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1038\/s41598-021-83487-4","article-title":"An in vitro study on factors affecting endotoxin neutralization in human plasma using the Limulus amebocyte lysate test","volume":"11","author":"Harm","year":"2021","journal-title":"Sci Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1373255","article-title":"The neutralizing effect of heparin on blood-derived antimicrobial compounds: impact on antibacterial activity and inflammatory response","volume":"15","author":"Cont","year":"2024","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00035-06","article-title":"Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa","volume":"50","author":"Bergen","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2022.121047","article-title":"Supramolecular interaction of ofloxacin drug with p-sulfonatocalix[6]arene: metal-ion responsive fluorescence behavior and enhanced antibacterial activity","volume":"370","author":"Siddharthan","year":"2023","journal-title":"J Mol Liq"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1039\/d2ob01381a","article-title":"Vancomycin mimicry: towards new supramolecular antibiotics","volume":"20","author":"Flint","year":"2022","journal-title":"Org Biomol Chem"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2018.03.028","article-title":"Lipopeptide daptomycin: Interactions with bacterial and phospholipid membranes, stability of membrane aggregates and micellation in solution","volume":"1860","author":"Liu","year":"2018","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky239","article-title":"Pharmacokinetics of intravenous and nebulized gentamicin in critically ill patients","volume":"73","author":"Boisson","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2174\/1573411012666160822114607","article-title":"Determination of imipenem and cilastatin in medicinal products by micellar electrokinetic chromatography","volume":"13","author":"Karpiuk","year":"2017","journal-title":"Curr Anal Chem"},{"key":"B38","volume-title":"Performance standards for antimicrobial susceptibility testing, M100","year":"2020"},{"key":"B39","article-title":"The antagonism between actinomycetes and soil bacteria","volume":"6","author":"Nakhimovskaia","year":"1937","journal-title":"Microbiology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/00010694-194210000-00008","article-title":"Distribution of antagonistic actinomycetes in nature","volume":"54","author":"Waksman","year":"1942","journal-title":"Soil Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2010.05861.x","article-title":"Production of antibiotic substances by actinomycetes","volume":"1213","author":"Waksman","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1021\/np200906s","article-title":"Natural products as sources of new drugs over the 30 years from 1981 to 2010","volume":"75","author":"Newman","year":"2012","journal-title":"J Nat Prod"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.11.010","article-title":"Antibiotic discovery: history, methods and perspectives","volume":"53","author":"Durand","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.106","article-title":"Prioritized current unmet needs for antibacterial therapies","volume":"96","author":"Spellberg","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/frans.2023.1154391","article-title":"Heparin increases the antibiotic efficacy of colistin","volume":"3","author":"Szekeres","year":"2023","journal-title":"Front Anal Sci"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1038\/s41598-024-52735-8","article-title":"Heparin enables the reliable detection of endotoxin in human serum samples using the Limulus amebocyte lysate assay","volume":"14","author":"Harm","year":"2024","journal-title":"Sci Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-0420","article-title":"Influence of gender on the outcome of severe sepsis: a reappraisal","volume":"132","author":"Adrie","year":"2007","journal-title":"Chest"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31818b8c6b","article-title":"Early intravenous unfractionated heparin and mortality in septic shock","volume":"36","author":"Zarychanski","year":"2008","journal-title":"Crit Care Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-014-0563-4","article-title":"Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis","volume":"18","author":"Wang","year":"2014","journal-title":"Crit Care"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1186\/s12871-021-01545-w","article-title":"Unfractionated heparin improves the clinical efficacy in adult sepsis patients: a systematic review and meta-analysis","volume":"22","author":"Fu","year":"2022","journal-title":"BMC Anesthesiol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/burnst\/tkac029","article-title":"Early prophylactic anticoagulation with heparin alleviates mortality in critically ill patients with sepsis: a retrospective analysis from the MIMIC-IV database","volume":"10","author":"Zou","year":"2022","journal-title":"Burns Trauma"},{"key":"B52","article-title":"Therapeutic effects of early administration of low-dose heparin in patients with severe sepsis","volume":"44","author":"Zhang","year":"2006","journal-title":"Chin J Surg"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31819c06bc","article-title":"Unfractioned heparin for treatment of sepsis: a randomized clinical trial (The HETRASE Study)","volume":"37","author":"Jaimes","year":"2009","journal-title":"Crit Care Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000000763","article-title":"The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis","volume":"43","author":"Zarychanski","year":"2015","journal-title":"Crit Care Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14885","article-title":"The role of heparin in sepsis: much more than just an anticoagulant","volume":"179","author":"Li","year":"2017","journal-title":"Br J Haematol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12959-024-00653-0","article-title":"Heparin therapy in sepsis and sepsis-associated disseminated intravascular coagulation: a systematic review and meta-analysis","volume":"22","author":"Totoki","year":"2024","journal-title":"Thromb J"},{"key":"B57","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/ejh.13520","article-title":"Anticoagulation strategies in extracorporeal circulatory devices in adult populations","volume":"106","author":"Kato","year":"2021","journal-title":"Eur J Haematol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58121783","article-title":"Anticoagulation management during extracorporeal membrane oxygenation-a mini-review","volume":"58","author":"Bur\u0161a","year":"2022","journal-title":"Med (Kaunas)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-007-0212-8","article-title":"The endothelial glycocalyx: composition, functions, and visualization","volume":"454","author":"Reitsma","year":"2007","journal-title":"Pflugers Arch"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1097\/01.mol.0000181325.08926.9c","article-title":"The endothelial glycocalyx: a potential barrier between health and vascular disease","volume":"16","author":"Nieuwdorp","year":"2005","journal-title":"Curr Opin Lipidol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.711003","article-title":"The endothelial glycocalyx as a double-edged sword in microvascular homeostasis and pathogenesis","volume":"9","author":"Villalba","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13054-018-2292-6","article-title":"The glycocalyx: a novel diagnostic and therapeutic target in sepsis","volume":"23","author":"Uchimido","year":"2019","journal-title":"Crit Care"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1708169\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:33:22Z","timestamp":1762842802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1708169\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":62,"alternative-id":["10.3389\/fimmu.2025.1708169"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1708169","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"article-number":"1708169"}}